External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy

BMC Nephrology

Research Article

Johan De Meester¹  Patrick Peeters²  Nic Veys²  Wim Van Biesen²  Wim Lemahieu³  Bart De Moor⁴ 

[1] Renal Division, AZ Nikolaas, St-Niklaas, Belgium;Renal Division, Department Of Internal Medicine, Ghent University Hospital, Ghent, Belgium;Renal Division, Imelda Ziekenhuis, Bonheiden, Belgium;Renal Division, Jessa Hospital, Hasselt, Belgium;

关键词: Chronic Obstructive Pulmonary Disease;    Renal Replacement Therapy;    Risk Stratification;    Shared Decision;    Geriatric Assessment;   

DOI  :  10.1186/s12882-016-0253-3

 received in 2015-12-04, accepted in 2016-03-31,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundShared decision making is nowadays acknowledged as an essential step when deciding on starting renal replacement therapy. Valid risk stratification of prognosis is, besides discussing quality of life, crucial in this regard. We intended to validate a recently published risk stratification model in a large cohort of incident patients starting renal replacement therapy in Flanders.MethodsDuring 3 years (2001–2003), the data set collected for the Nederlandstalige Belgische Vereniging voor Nefrologie (NBVN) registry was expanded with parameters of comorbidity. For all incident patients, the abbreviated REIN score(aREIN), being the REIN score without the parameter “mobility”, was calculated, and prognostication of mortality at 3, 6 and 12 month after start of renal replacement therapy (RRT) was evaluated.ResultsThree thousand four hundred seventy-two patients started RRT in Flanders during the observation period (mean age 67.6 ± 14.3, 56.7 % men, 33.6 % diabetes). The mean aREIN score was 4.1 ± 2.8, and 56.8, 23.1, 12.6 and 7.4 % of patients had a score of ≤4, 5–6, 7–8 or ≥9 respectively. Mortality at 3, 6 and 12 months was 8.6, 14.1 and 19.6 % in the overall and 13.2, 21.5 and 31.9 % in the group with age >75 respectively. In RoC analysis, the aREIN score had an AUC of 0.74 for prediction of survival at 3, 6 and 12 months. There was an incremental increase in mortality with the aREIN score from 5.6 to 45.8 % mortality at 6 months for those with a score ≤4 or ≥9 respectively.ConclusionThe aREIN score is a useful tool to predict short term prognosis of patients starting renal replacement therapy as based on comorbidity and age, and delivers meaningful discrimination between low and high risk populations. As such, it can be a useful instrument to be incorporated in shared decision making on whether or not start of dialysis is worthwhile.

【 授权许可】

CC BY   
© Peeters et al. 2016